The University of Texas at Austin

Contoro Robotics specializes in developing AI-powered robots for safe trailer and container unloading. Their robots autonomously pick up cases, recognize text, and palletize them, minimizing human intervention and robot downtime.

ClearCam Inc. is a medical technology company based in Austin, Texas, founded in 2018. It specializes in developing innovative tools that enhance visibility for surgeons during laparoscopic procedures. The company's flagship product, the ClearCam Kelling, is a laparoscope lens cleaning device designed to maintain a clear visual field without necessitating the removal of the laparoscope from the surgical site. This device attaches directly to the scope and does not require additional supplies, thereby streamlining surgical processes, saving time, and improving overall safety for patients and medical staff alike.

Jurata Thin Film develops thin films that enhance the storage and delivery of vaccines and biologics. Its technology enables long-term stability at room temperature or higher, eliminating the need for refrigeration and improving global accessibility to these vital therapies.

The Giant Magellan Telescope will be one member of the next class of super giant earth-based telescopes that promises to revolutionize Their view and understanding of the universe. It will be constructed in the Las Campanas Observatory in Chile. Commissioning of the telescope is scheduled to begin in 2021.

EnergyX is a clean technology company founded in 2018 and headquartered in Fort Lauderdale, Florida. It specializes in optimizing the lithium extraction process and developing solid-state battery technologies. The company aims to support the transition to sustainable energy by addressing all aspects of the battery supply chain, from brine lithium extraction and refinement to the advancement of solid-state batteries that offer enhanced safety and energy density. By innovating the lithium extraction process, EnergyX enables clients to reduce production costs, thereby facilitating a more efficient and economical shift towards clean energy solutions.

Texas Guadaloop is dedicated to researching and developing innovative transportation systems, specifically focusing on hyperloop technology. The company has created a pod prototype that employs air-bearing technology to achieve levitation, resulting in zero friction within hyperloop tubing. This advancement allows for significantly reduced drag, enabling transportation at speeds of up to 700 mph. Texas Guadaloop aims to provide a more sustainable alternative for transporting people and goods, addressing the growing demands of the transportation sector while offering a cost-effective solution compared to traditional magnetic levitation systems.

AnCatt is a pioneering company recognized for developing the world's only heavy-metal free high-performance anti-corrosion coatings. After 50 years of research and development, AnCatt has created the iBarrierTM coating, which not only meets stringent environmental standards but also surpasses existing products in performance metrics, including durability and ease of application. The company offers three product lines: a wash primer system, an epoxy primer system, and a waterborne epoxy system, the latter being the only high-performance waterborne epoxy anti-corrosion paint available. AnCatt's innovative technology utilizes a conductive polymer nano-dispersion to replace hazardous anti-corrosion pigments such as chromate, lead, and zinc, making it suitable for protecting various structures, including steel, pipelines, and bridges. Founded in 2008, AnCatt has scaled its manufacturing processes and holds patents and trademarks in the U.S., EU, and Canada, positioning itself to lead the $30 billion global anti-corrosion coating market through a focus on sustainability and advanced performance.

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Plano, Texas, that specializes in developing novel therapeutics for serious and life-threatening diseases. The company targets molecular pathways involved in cellular metabolism and inflammation, with a focus on conditions such as chronic kidney disease (CKD), pulmonary arterial hypertension, and neurodegenerative diseases. Reata's pipeline includes bardoxolone methyl, which is undergoing Phase III trials for CKD caused by Alport syndrome and for pulmonary arterial hypertension associated with connective tissue disease. Additionally, omaveloxolone is in Phase II trials for Friedreich’s ataxia. The company is also exploring RTA 901 for neurological conditions and has RORgT inhibitors in preclinical development for autoimmune and inflammatory diseases. Reata has established strategic collaborations for the development and commercialization of its therapies in various Asian markets and with AbbVie for certain Nrf2 activators. Founded in 2002 and rebranded in 2005, Reata Pharmaceuticals is committed to advancing innovative treatments for complex medical challenges.